Sirdás sisdollui
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Giella
Buot deaivamat
Bajilčálus
Dahkki
Fáddá
Hildobáiki
ISBN/ISSN
Fáddágilkor
Viečča
Aiddostahtton
Osteoprotegerin inhibits the d...
Čujuhandieđut
Deakstadieđáhus
Sádde šleađgaboasttain
Čálit
Doalvvo čujuhusa
Doalvun: RefWorks
Doalvun: EndNoteWeb
Doalvun: EndNote
Bissovaš liŋka
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Čájet eará veršuvnnaid (1)
Bibliográfalaš dieđut
Váldodahkkit:
Croucher, P
,
Shipman, C
,
Perry, M
,
Lippitt, J
,
Asosingh, K
,
van Beek, E
,
Van Camp, B
,
Russell, R
,
Dunstan, C
,
Vanderkerken, K
Materiálatiipa:
Journal article
Almmustuhtton:
2001
Oažžasuvvandieđut
Govvádus
Eará veršuvnnat (1)
Geahča maid
Bargiidšearbma
Geahča maid
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
Dahkki: Croucher, P, et al.
Almmustuhtton: (2001)
Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
Dahkki: Croucher, P, et al.
Almmustuhtton: (2000)
Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Dahkki: Croucher, P, et al.
Almmustuhtton: (2003)
Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
Dahkki: Croucher, P, et al.
Almmustuhtton: (2001)
Osteoprotegerin and the development of myeloma bone disease
Dahkki: Croucher, P, et al.
Almmustuhtton: (2004)